New hope for breast cancer patients: An FDA panel has backed a pre-surgery drug that doctors say could help women fight breast cancer earlier — and live longer cancer-free. Full FDA approval could come as early as next month. NBC’s John Yang reports.
Perjeta won the backing of U.S. regulatory advisers to potentially become the first pre-surgical drug treatment for breast cancer that could lead to a less-invasive procedure.
The benefits of expanding use of Perjeta to early-stage breast cancer patients outweigh the risks, advisers to the Food and Drug Administration voted 13-0 today in Silver Spring, Maryland. The drug was approved last year for patients with HER2-positive advanced breast cancer that has spread.